Major Market disruptions for Birth Control Products in 2013 forecast

Durham, NC (PRWEB) 18 October 2012 360 According to a recent Phoenix Marketing? Birth Control Market Tracking Study of 1,254 women who are currently ...


Durham, NC (PRWEB) 18 October 2012

360 According to a recent Phoenix Marketing? Birth Control Market Tracking Study of 1,254 women who are currently using oral contraceptives brand products, half (50.8%) likely to switch to a generic form or another method of contraception. Oral contraceptives are used, the largest share (67%) of prescription contraceptives for women 18-45, but their market shares could shift dramatically in 2013. One in five (23%) women with branded oral contraceptives must be changed probably a longer-acting form of contraception: the intrauterine device (IUD), the leading alternative, followed by vaginal ring, transdermal patch, injection under the skin graft, followed by permanent birth through surgery-free implants or tubal ligation.?

Phoenix Healthcare, a division of Phoenix Marketing International, interviews 1,000 women each month, to learn to use any form of contraception, whether they recently talked to their doctor about methods and brands. Phoenix also tracks the impact of branded direct-to-consumer (DTC) to learn print and digital ads, websites and social media, and women to be informed about contraception, which they in turn discuss with their doctor.

Phoenix Healthcare birth control audit is part of a growing family of disease category consumer studies that offer exclusive Phoenix 360? Market View Top. Phoenix Healthcare 360? MarketView studies currently cover 40% of all DTC spending in the United States with the research in the following categories:. Contraceptives, dyslipidemia, schizophrenia, rheumatoid arthritis, plaque psoriasis, Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, and Mens Health Pursues a partial list of the most important brands in these programs include: Abilify, Actemra, AndroGel, Cialis, Cimzia, Ella, Enbrel, Essure, Generess FE, Humira, Invega Sustenna, Januvia, Levitra, Lo Loestrin FE, Mirena, Niaspan, Orencia, Ortho Evra and Ortho Tricyclic Lo, ParaGard, Plan B, Rapiflo, Remicade, Rituxan, Seroquel XR, Simponi, Stelara, Uloric, Viagra, Victoza and Zyprexa Relprevv.

For more information on the nature of the brand tracking information in the 360? Contraceptive Market View? Study contact John Duggan at 508-315-6184 or john (dot) duggan (at) phoenixmi (dot) com.


Leave a Reply